预测首次接受唑来膦酸治疗的未使用双膦酸盐骨质疏松患者的急性期反应发热风险
本研究基于475例连续纳入的未使用双膦酸盐的骨质疏松患者,于2016年3月至2021年3月在江苏大学附属昆山医院首次接受静脉唑来膦酸治疗,利用单变量和多变量逻辑回归建立三个发热阈值(37.3°C、38.0°C、38.5°C)的列线图预测模型,并评估区分度、校准度和临床实用性,同时进行内部和外部验证。稳定预测因子包括年龄、血清25-羟基维生素D、血清总钙和外周血红细胞计数,均与APR发热风险负相关。三个模型的AUC分别为0.828、0.825和0.879,校准曲线显示预测与观察一致性良好。
要点
- 年龄、血清25-羟基维生素D、血清总钙和外周血红细胞计数是与APR发热风险负相关的稳定预测因子。
- 模型A、B、C的AUC分别为0.828(95%CI 0.782-0.874)、0.825(95%CI 0.767-0.883)和0.879(95%CI 0.824-0.934)。
- 三个列线图校准曲线均显示预测与观察一致性良好。
核心结论
- 本研究开发并验证了列线图预测模型,可预测未使用双膦酸盐的骨质疏松患者首次输注唑来膦酸后的APR发热风险。
研究设计与样本
- 研究纳入2016年3月至2021年3月在江苏大学附属昆山医院首次接受静脉唑来膦酸治疗的475例连续未使用双膦酸盐的骨质疏松患者,采用单变量和多变量逻辑回归建立预测模型,并开发三个发热阈值(37.3°C、38.0°C、38.5°C)的列线图。
主要发现
- 稳定预测因子为年龄、血清25-羟基维生素D、血清总钙和外周血红细胞计数,均与APR发热风险负相关。
- 模型A、B、C的AUC分别为0.828(95%CI 0.782-0.874)、0.825(95%CI 0.767-0.883)和0.879(95%CI 0.824-0.934)。
- 三个列线图的校准曲线显示预测与观察一致性良好。
关键数值与推荐
- 模型A(发热阈值37.3°C)的AUC为0.828(95%CI 0.782-0.874)。
- 模型B(发热阈值38.0°C)的AUC为0.825(95%CI 0.767-0.883)。
- 模型C(发热阈值38.5°C)的AUC为0.879(95%CI 0.824-0.934)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To devise a precise and efficient tool for predicting the individualized risk of acute-phase response (APR) in bisphosphonate (BP)-naive osteoporotic (OP) patients, receiving their first intravenous dose of zoledronate (ZOL). METHODS: The baseline clinical and laboratory data of 475 consecutive BP-naive OP patients, who received their first intravenous dose of ZOL between March 2016 and March 2021 in the Affiliated Kunshan Hospital of Jiangsu University, were chosen for analysis. Univariate and multivariable logistic regression models were generated to establish candidate predictors of APR fever risk, using three distinct fever thresholds, namely, 37.3 °C (model A), 38.0 °C (model B), and 38.5 °C (model C). Next, using predictor regression coefficients, three fever-threshold nomograms were developed. Discrimination, calibration, and clinical usefulness of each predicting models were then assessed using the area under the curve (AUC), calibration curve (CC), and decision curve analysis (DCA). The internal and external model validations were then performed. RESULTS: The stable predictors were age, serum 25-hydroxy vitamin D, serum total calcium, and peripheral blood erythrocytes count. These were negatively associated with the APR fever risk. The AUCs of models A, B, and C were 0.828 (95% confidence intervals [CI], 0.782 to 0.874), 0.825 (95% CI, 0.767 to 0.883), and 0.879 (95% CI, 0.824 to 0.934), respectively. Good agreement was observed between the predictions and observations in the CCs of all three nomograms. CONCLUSIONS: This study developed and validated nomogram prediction models that can predict APR fever risk in BP-naive OP patients receiving their first infusion of ZOL.
引用
- Lu K, Shi Q, Gong YQ, et al. Predicting the acute-phase response fever risk in bisphosphonate-naive osteoporotic patients receiving their first dose of zoledronate. Osteoporos Int. 2022. PMID: 35920895. doi:10.1007/s00198-022-06493-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。